Article

Stopping Inflammatory Arthritis at its Source

Author(s):

Compounds in the body may help reduce inflammation and prevent damage to healthy tissues for arthritis patients and patients with other inflammatory diseases.

Compounds in the body may help reduce inflammation and prevent damage to healthy tissues for arthritis patients and patients with other inflammatory diseases, according to findings published in the Proceedings of the National Academy of Sciences (PNAS).

Researchers from the University of Edinburgh observed human cells to determine if inflammation in the body could be restricted in patients with arthritis or other inflammatory diseases could be controlled.

“This study reveals yet another layer of the immune system’s complex control system,” Stephen Simpson, Director of research and programs for Arthritis Research UK, who funded the study, explained in a press release. “Understanding how the immune system works both in health and disease is crucial if we are to develop new and improved treatments for inflammatory conditions such as rheumatoid arthritis.”

The researchers’ previous work led them to compounds called alpha defensins, which are absorbed by macrophages. The alpha defensins aid the body in stopping the spread and breeding of bacteria. The alpha defensins are released by apoptotic neutrofils, a peptide responsible for acute inflammation in response to tissue injury or infection.

When macrophages take in the alpha defensins, compounds prevent macrophages from producing cytokines — the cause of patients’ inflammation. The researchers believe that one path to limiting the body’s excessive inflammation is through restricting damage to healthy tissue while avoiding compromising the body’s ability to rid itself of the infection. They called the alpha defensins a “molecular brake” for macrophage related inflammation.

“This discovery opens the door to new approaches for the treatment and prevention of chronic inflammation,” Dr. Mohini Gray continued in the statement. “We are hopeful that with further research, these treatments could be exploited in the near future.”

The team believes that with further research, they may be able to prevent inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis from flaring up in the first place. They also explained that their findings could lead to new therapies for chronic inflammatory disorders in the future.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.